Bebtelovimab
An anti-RBD (SARS-CoV-2 Spike) monoclonal antibody.
General information
Bebtelovimab is a fully human IgG1 monoclonal antibody targeting receptor binding domain (RBD) of SARS-CoV-2 Spike protein. It was identified in COVID-19 convalescent patient’s peripheral blood mononuclear cells. The antibody targets a relatively unique and conserved epitope within the RBD. It competes with S309 and Imdevimab for Spike binding. Bebtelovimab was shown to potently neutralize authentic SARS-CoV-2 strains Alpha, Beta, and Delta and pseudoviruses derived from various strains, including Omicron B.1.1.529 and BA.2 (Westendorf et al., 2022).
Bebtelovimab (by Eli Lilly and Company) has been granted and emergency use authorization for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12+ years of age, 40+ kg body weight) by the FDA in the USA.
Bebtelovimab on DrugBank
Bebtelovimab on Wikipedia
Synonyms
LY-CoV1404; LY-3853113
Marketed as
BEBTELOVIMAB
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
Spike protein Spike variant Protein factor In vitro Antibody In silico |
in silico; HEK293T cells; (lentiviral) SARS-CoV-2 pseudotypes (D614G, Delta, BA.1, and BA.2) | 5.82 | The antibody retained its capacity to neutralize the Omicron variants BA.1 and BA.2 in vitro. |
Jun/18/2022 |
|
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Spike protein Spike variant Novel compound Biophysical assay Protein factor In vitro Mechanism Antibody In silico |
In silico; biophysical assay; CHO cells (binding assay); Vero E6 cells; 293T-ACE2 cells; 293 flpin-TMPRSS2-ACE2 cells; peripheral blood mononuclear cells (for mAb identification); SARS-CoV-2 (authentic – various strains; pseudotyped – VSV/lentiviral) | 9.42 | The antibody targets a relatively unique and conserved epitope within the RBD. It competes with S309 and Imdevimab for Spike binding. Bebtelovimab was shown to potently neutralize authentic SARS-CoV-2 strains Alpha, Beta, and Delta and pseudoviruses derived from various strains, including Omicron B.1.1.529 and BA.2. |
Apr/20/2022 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.
|
Apr/22/2022 |
|
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
|
Mar/03/2022 |
